Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Citations
4,855 citations
4,408 citations
2,904 citations
2,450 citations
1,911 citations
Cites background from "Inhibition of SARS-CoV-2 Infections..."
...For example, examining the efficacy of recombinant human ACE2 to act as a decoy receptor or the effect of ‘‘ACE inhibitors’’ in patients with, or at risk for, COVID-19 will require careful experimentation in appropriate models together with well-controlled clinical trials (Hofmann et al., 2004; Monteil et al., 2020; Vaduganathan et al., 2020)....
[...]
References
44,587 citations
36,578 citations
"Inhibition of SARS-CoV-2 Infections..." refers background in this paper
...We reported that injecting SARS-CoV spike into mice decreased ACE2 expression levels, thereby worsening lung injury (Imai et al., 2005; Kuba et al., 2005)....
[...]
...Importantly, we reported that ACE2 protects from lung injury, based on its catalytic domain, and that ACE2 is the critical in vivo SARS-CoV spike glycoprotein receptor (Imai et al., 2005; Kuba et al., 2005)....
[...]
...ACE2 was identified as the functional SARS-CoV receptor in vitro and, by our group, in vivo (Imai et al., 2005; Kuba et al., 2005)....
[...]
...Importantly, we reported that ACE2 protects from lung injury, based on its catalytic domain, and ACE2 is the critical in vivo SARS-CoV spike glycoprotein receptor (Imai et al., 2005; Kuba et al., 2005)....
[...]
22,622 citations
21,455 citations
20,189 citations